A zebrafish model of combined saposin deficiency identifies acid sphingomyelinase as a potential therapeutic target
Disease Models & Mechanisms · 2023
DOI: 10.1242/dmm.049995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2023. Verfasst von Tejia Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA. Hauptthemen laut MEDLINE: Lysosomal Storage Diseases, Sphingolipidoses. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NHGRI NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Sphingolipidoses are a subcategory of lysosomal storage diseases (LSDs) caused by mutations in enzymes of the sphingolipid catabolic pathway. Like many LSDs, neurological involvement in sphingolipidoses leads to early mortality with limited treatment options. Given the role of myelin loss as a major contributor toward LSD-associated neurodegeneration, we investigated the pathways contributing to demyelination in a CRISPR-Cas9-generated zebrafish model of combined saposin (psap) deficiency. psap knockout (KO) zebrafish recapitulated major LSD pathologies, including reduced lifespan, reduced lipid storage, impaired locomotion and severe myelin loss; loss of myelin basic protein a (mbpa) mRNA was progressive, with no changes in additional markers of oligodendrocyte differentiation. Brain transcriptomics revealed dysregulated mTORC1 signaling and elevated neuroinflammation, where increased proinflammatory cytokine expression preceded and mTORC1 signaling changes followed mbpa loss. We examined pharmacological and genetic rescue strategies via water tank administration of the multiple sclerosis drug monomethylfumarate (MMF), and crossing the psap KO line into an acid sphingomyelinase (smpd1) deficiency model. smpd1 mutagenesis, but not MMF treatment, prolonged lifespan in psap KO zebrafish, highlighting the modulation of acid sphingomyelinase activity as a potential path toward sphingolipidosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA.
- Bioinformatic Analysis Shared Resource, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Neurobiology and Molecular Medicine Program, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
- Electron Microscopy Core Laboratory, University of Utah, Salt Lake City, UT 84112, USA.
- Harvard Center for Mass Spectrometry, Harvard University, Cambridge, MA 02138, USA.
ORCID-Profile: Tejia Zhang, Ivy Alonzo, Chelsea Herdman, Randall T Peterson
Förderung
- NHLBI NIH HHS
- NHGRI NIH HHS
- NIEHS NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- National Institutes of Health
- Harvard NeuroDiscovery Center
- L. S. Skaggs Presidential Endowed Chair
Zitieren
APA
Zhang, T., Alonzo, I., Stubben, C., Geng, Y., Herdman, C., Chandler, N., Doane, K. P., Pluimer, B. R., Trauger, S. A., & Peterson, R. T. (2023). A zebrafish model of combined saposin deficiency identifies acid sphingomyelinase as a potential therapeutic target. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.049995
Vancouver
Zhang T, Alonzo I, Stubben C, Geng Y, Herdman C, Chandler N, et al. A zebrafish model of combined saposin deficiency identifies acid sphingomyelinase as a potential therapeutic target. Disease Models & Mechanisms. 2023. doi:10.1242/dmm.049995
BibTeX
@article{Zhang2023,
author = {Zhang, Tejia and Alonzo, Ivy and Stubben, Chris and Geng, Yijie and Herdman, Chelsea and Chandler, Nancy and Doane, Kim P and Pluimer, Brock R and Trauger, Sunia A and Peterson, Randall T},
title = {A zebrafish model of combined saposin deficiency identifies acid sphingomyelinase as a potential therapeutic target},
journal = {Disease Models & Mechanisms},
year = {2023},
doi = {10.1242/dmm.049995}
}
EUVIMED